{"id":397186,"date":"2020-12-10T08:03:10","date_gmt":"2020-12-10T13:03:10","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=397186"},"modified":"2020-12-10T08:03:10","modified_gmt":"2020-12-10T13:03:10","slug":"solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/","title":{"rendered":"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution"},"content":{"rendered":"

\nAgreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services\u2019 Network
\n<\/h2>\n
\n

NASHUA, N.H. and DALLAS, Dec. 10, 2020 (GLOBE NEWSWIRE) — iCAD, Inc<\/a>. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography<\/a>, the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography\u2019s nationwide network with its latest artificial intelligence (AI) breast health solutions, including ProFound AI\u00ae for DBT and ProFound AI Risk, the first and only clinical decision support tool to provide an accurate two-year breast cancer risk estimation based on a screening mammogram.<\/p>\n

\u201cAfter a thorough evaluation of all available AI solutions, we have chosen iCAD\u2019s ProFound AI platform as our sole breast health AI solution to integrate with our Hologic 3D mammography systems throughout our entire network,\u201d said Grant Davies, President and Chief Executive Officer of Solis Mammography. \u201cProFound AI will further enhance patient care and outcomes for the over one million women we serve while also supporting our continued growth and expansion.\u201d<\/p>\n

\n ProFound AI for DBT<\/a> is a high-performing workflow solution trained with the latest in deep-learning AI capabilities. It assists radiologists by rapidly and accurately analyzing each individual DBT image to identify potentially malignant lesions. The ProFound AI platform powered by Panorama is compatible with all leading mammography systems and allows for seamless integration with major PACS for decision support capabilities across large networks.<\/p>\n

\u201cOur partnership with Solis underscores our ongoing commitment to improving women\u2019s health and we are thrilled that even more women across the United States will benefit from our revolutionary technology that is helping to improve lives,\u201d said Michael Klein, Chairman and CEO of iCAD. \u201cProFound AI powered by Panorama offers unparalleled benefits to patients and radiologists alike, including a clinically proven improvement in sensitivity and specificity, which dramatically improves reading accuracy for mammograms and reduces the rate of false positives. Likewise, with the addition of our recently introduced ProFound AI Risk offering, we believe we will move mammography from what is today an age-based screening paradigm to a risk-adjusted precision screening paradigm that is personalized for every woman.\u201d<\/p>\n

In September 2020, compelling research published in the peer-reviewed journal, Radiology<\/a> concluded that the ProFound AI Risk<\/a> model is effective in identifying women at a high likelihood of being diagnosed with breast cancer within two years of a negative screening mammogram and in possible need of supplemental screening.<\/p>\n

\u201cWe\u2019ve reinvented the mammography\u00a0experience with a compassionate, patient-focused approach,\u201d said Alexander Sardi\u00f1a, MD, Chief Medical Officer at Solis Mammography. \u201cWe ensure that all of our facilities are equipped with the latest, state-of-the-art screening and diagnostic technologies designed to improve the patient experience and offer women peace of mind. The recent adoption of ProFound AI for DBT throughout our network will allow our radiologists to quickly and accurately evaluate their patients\u2019 3D mammography images and aid in the identification of suspicious lesions earlier. In addition, the ability to provide a short-term, two-year breast cancer risk assessment will significantly enhance clinical decision making and further complement the armamentarium of breast cancer diagnostic and therapeutic tools available at Solis Mammography.\u201d<\/p>\n

ProFound AI for DBT is proven to curtail workflow challenges substantially by reducing radiologists\u2019 reading time by 52.7%, thereby reducing by half the amount of time it takes radiologists to read 3D mammography datasets. Additionally, the platform improved radiologists\u2019 performance measured by Area Under the Curve (AUC) by nearly 6% and reduced unnecessary patient recall rates by more than 7%.1<\/sup><\/p>\n

\n About Solis Mammography<\/strong>
\n
\n Solis Mammography<\/a> is the nation\u2019s largest independent provider of breast screening and diagnostic services. It operates more than 80 Solis-branded centers in 11 states, as well as seven offices in the Washington, DC metro area through its affiliate brand, Washington Radiology. Solis has been dedicated to helping women achieve and maintain breast health and peace of mind for more than 30 years and more than five million procedures. As a pioneer and innovator in 3D mammography, Solis has stayed at the forefront of breast health by continuing to deliver a better experience and a more accurate mammogram to the generations of women we serve.<\/p>\n

\n About iCAD, Inc.<\/strong>
\n
Headquartered in Nashua, NH, iCAD<\/a> is a global medical technology leader providing innovative cancer detection and therapy solutions. ProFound AI\u00ae is a high-performing workflow solution for 2D and 3D mammography, or digital breast tomosynthesis (DBT), featuring the latest in deep-learning artificial intelligence (AI). In 2018, ProFound AI for DBT became the first AI software for DBT to be FDA-cleared; it was also CE marked and Health Canada licensed that same year. It provides crucial information, such as Certainty of Finding lesion and Case Scores, which assists in clinical decision-making and improving reading efficiency. ProFound AI Risk is currently available on an introductory basis for 2D mammography and will subsequently be available for the rapidly growing 3D mammography market. For more information, visit\u00a0www.icadmed.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
Certain statements contained in this News Release constitute \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the benefits of the Company\u2019s agreement with Solis and future prospects for the Company\u2019s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company\u2019s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company\u2019s filings with the Securities and Exchange Commission. The words \u201cbelieve,\u201d \u201cdemonstrate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cwill,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201clikely,\u201d \u201cseek,\u201d and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http:\/\/www.icadmed.com and on the SEC\u2019s website at http:\/\/www.sec.gov<\/a>.\u00a0<\/p>\n

Contacts:<\/p>\n

Media inquiries:
Amy Cook, iCAD
+1-925-200-2125
acook@icadmed.com<\/a><\/p>\n

Investor relations:
Jeremy Feffer, LifeSci Advisors
+1-212-915-2568
jeremy@lifesciadvisors.com<\/a><\/p>\n

\n 1<\/sup> Conant, E et al. (2019). Improving Accuracy and Efficiency with Concurrent Use of Artificial Intelligence for Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1 (4). Accessed via https:\/\/pubs.rsna.org\/doi\/10.1148\/ryai.2019180096<\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services\u2019 Network NASHUA, N.H. and DALLAS, Dec. 10, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography, the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography\u2019s nationwide network with its latest artificial intelligence (AI) breast health solutions, including ProFound AI\u00ae for DBT and ProFound AI Risk, the first and only clinical decision support tool to provide an accurate two-year breast cancer risk estimation based on a screening mammogram. \u201cAfter … <\/p>\n

Continue reading “Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-397186","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSolis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services\u2019 Network NASHUA, N.H. and DALLAS, Dec. 10, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography, the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography\u2019s nationwide network with its latest artificial intelligence (AI) breast health solutions, including ProFound AI\u00ae for DBT and ProFound AI Risk, the first and only clinical decision support tool to provide an accurate two-year breast cancer risk estimation based on a screening mammogram. \u201cAfter … Continue reading "Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T13:03:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution\",\"datePublished\":\"2020-12-10T13:03:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/\"},\"wordCount\":1262,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/\",\"name\":\"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg=\",\"datePublished\":\"2020-12-10T13:03:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/","og_locale":"en_US","og_type":"article","og_title":"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution - Market Newsdesk","og_description":"Agreement Positions Both Companies for Growth; Leading-edge AI Technology to be Installed Across Largest Independent Provider of Mammography and Breast Health Services\u2019 Network NASHUA, N.H. and DALLAS, Dec. 10, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, and Solis Mammography, the largest independent provider of mammography and breast health services in the United States, today announced a five-year partnership whereby iCAD will provide Solis Mammography\u2019s nationwide network with its latest artificial intelligence (AI) breast health solutions, including ProFound AI\u00ae for DBT and ProFound AI Risk, the first and only clinical decision support tool to provide an accurate two-year breast cancer risk estimation based on a screening mammogram. \u201cAfter … Continue reading \"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-10T13:03:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution","datePublished":"2020-12-10T13:03:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/"},"wordCount":1262,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/","name":"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg=","datePublished":"2020-12-10T13:03:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5OTk5NyMzODY1MzQ3IzIwMDg2Mjg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/solis-mammography-adopts-icads-profound-ai-platform-powered-by-panorama-with-short-term-breast-cancer-risk-assessment-solution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Solis Mammography Adopts iCAD\u2019s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397186","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=397186"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397186\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=397186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=397186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=397186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}